Kala Bio narrows net loss sharply in preliminary third-quarter 2026 results
The company cut its quarterly net loss by about 90% year over year while continuing to build out its AI platform business alongside its biologics pipeline.
KALA BIO, Inc. announced preliminary, unaudited financial results for the quarter ended September 30, 2026 on November 9, 2026. The company said it expects to file its Form 10-Q for the quarter with the SEC around November 16, 2026.1
The company reported a net loss of approximately $0.8 million for the third quarter of 2026, down from $7.6 million in the same period of 2025.1 For the nine-month period, net loss was approximately $4.0 million, compared with $27.7 million for the same period in 2025.1 As of September 30, 2026, the company held cash, cash equivalents and short-term investments of approximately $7.0 million, with no debt.1
Chief Executive Officer and Chief Financial Officer Avi Minkowitz said the company reduced its quarterly net loss by approximately 90% year over year and continues to develop the initiatives it has put in motion.1 He also thanked stockholders who attended the company's annual meeting held on November 3, 2026.
The release describes Kala as a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry, pairing a proprietary biologics pipeline that includes its mesenchymal stem cell secretome platform and FDA Orphan Drug- and Fast Track-designated product candidates with a scalable AI platform-as-a-service business.1 The company said it holds an exclusive worldwide license for the Researgency AI research platform from Younet, through which it intends to serve as a dedicated AI infrastructure partner for the biotechnology industry.1
The results are preliminary and unaudited, and final figures to be included in the Form 10-Q may differ.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.